Hot Investor Mandate: Venture Philanthropy Investor Deploys $1-2M in Seed and Series A Cardiovascular and Metabolic Technologies Globally

The firm is a U.S.-based philanthropic venture investor focused on accelerating the development of technologies for the diagnosis and treatment of cardiovascular and neurovascular diseases. The firm typically invests $1M–$2M per company and seeks to make approximately four to five new investments annually. The firm targets Seed and Series A companies and operates through an evergreen investment structure, supporting technologies that can achieve meaningful development milestones and attract subsequent institutional financing. The firm invests globally.

The firm invests across biotechnology, medical technology, diagnostics, and regenerative medicine, with a particular emphasis on cardiovascular, neurovascular, and metabolic diseases. Areas of interest include diabetes, dyslipidemia, obesity, and technologies addressing significant unmet clinical needs. The firm is broadly opportunistic regarding specific technologies and seeks innovations capable of improving patient outcomes and advancing treatment options. The firm prioritizes opportunities where investment capital can help companies achieve critical value-inflection milestones necessary for larger financing rounds.

From a company and management team perspective, the firm seeks technologies with clear potential to improve patient therapy and meaningful intellectual property protection. The firm places particular emphasis on a well-defined use of proceeds, achievable development milestones, and a clear understanding of the next financing round, including its anticipated size and potential sources. The firm favors companies capable of demonstrating measurable progress toward clinical and commercial development.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Early-Stage Venture Builder Seeks Pre-Seed and Series A Healthcare Technologies in the US

The firm is a U.S.-based venture capital and venture-building investor specializing in Pre-Seed through early Series A companies. The firm combines direct investment with strategic company development and frequently invests alongside other venture capital partners through co-investment structures. The firm supports early-stage companies that meet its investment criteria and helps prepare businesses for subsequent institutional financing. The firm primarily targets opportunities in the United States.

The firm invests in technologies that improve health, safety, and environmental outcomes for current and future generations. The firm is particularly interested in early-stage opportunities that require both capital and hands-on company-building support to translate innovative technologies into commercially viable products. The firm engages with companies as early as the Pre-Seed and pre-revenue stages and supports progression toward Series A readiness, emphasizing product-market fit, revenue planning, and the development of strong foundations for sustainable growth.

From a company and management team perspective, the firm seeks founders with meaningful experience in their respective fields and a willingness to collaborate closely with investors. A fully established management team is not required at the time of investment. The firm provides hands-on support in company formation, corporate structuring, management recruitment, fundraising, product development, commercialization, and strategic planning. The firm also assists with governance, contract negotiations, financial planning, and preparation for subsequent institutional investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Early-Stage Life Sciences VC Invests in First-in-Class Therapeutics, Diagnostics, and Medical Technologies in US, Canada, Europe

The firm is a U.S.-based venture capital investor focused on early-stage life sciences and healthcare companies. The firm invests through a dedicated life sciences fund and draws on extensive investment experience and industry relationships to support the translation of scientific discoveries into commercially viable healthcare products.

The firm primarily targets first-in-class innovations addressing significant unmet medical needs and invests across the United States, Canada, and Europe. The firm invests across therapeutics, medical devices, diagnostics, and digital health technologies. Areas of particular interest include oncology drug development, targeted therapeutics, innovative drug delivery technologies, molecular diagnostics, precision medicine, and healthcare technology platforms. The firm also supports companies developing technologies for improved disease detection, patient monitoring, and healthcare delivery. The firm prioritizes differentiated scientific and technological innovations with the potential to transform disease treatment, improve patient outcomes, and advance healthcare delivery.

From a company and management team perspective, the firm seeks scientists, clinicians, and entrepreneurs developing breakthrough life sciences technologies with strong scientific foundations and significant commercial potential. The firm prioritizes scientifically differentiated intellectual property, compelling scientific or clinical evidence, and clear pathways toward product development and commercialization. The firm values experienced, technically capable management teams and leverages its investment expertise and industry relationships to support company development, technology advancement, and long-term growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Healthcare Growth Equity Firm Invests $20-70M in Near Commercialization MedTech, Biopharma, and Diagnostics Companies

The firm is a healthcare-focused growth equity investor with offices in North America and Europe. The firm manages more than $1B in capital and typically invests $20M–$70M per company over the life of an investment. The firm considers both publicly traded and privately held companies and is open to equity investments and buyout opportunities. The firm primarily targets companies across North America and Europe.

The firm invests across medical technology, biopharmaceuticals, diagnostics, medical devices, life science tools, digital health, and veterinary medicine. The firm is broadly indication-agnostic and places significant emphasis on the clinical utility and health economics of potential investments. The firm primarily seeks later-stage companies with products that are already commercialized or approaching commercialization, favoring opportunities with demonstrated clinical value and clear commercial potential.

From a company and management team perspective, the firm seeks experienced leadership teams willing to work closely with investors to execute growth and commercialization strategies. The firm generally expects to take a board seat and actively participates in strategic decision-making. The firm is flexible regarding transaction structures and evaluates opportunities based on their clinical differentiation, commercial readiness, and potential for long-term value creation.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

BIOCHINA and Life Science Nation Team Up to Advance China–Global Biotech Partnerships

Collaboration connects Chinese innovation with international licensing partners at RESI JPM and BIOCHINA 2027

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

BOSTON and SUZHOU, China — Chinese biotech is changing the global partnering landscape. Life Science Nation (LSN) and Enmore BIO, organizer of BIOCHINA, are teaming up in 2027 to connect the companies driving that change with international licensing partners seeking their next opportunity.

The collaboration launches during J.P. Morgan Healthcare Week at RESI JPM, January 11–12 at the San Francisco Marriott Marquis, and continues at BIOCHINA, March 10–12 in Suzhou. Through reciprocal programs and coordinated outreach, the organizations will bring their communities together across two major life science gatherings. At RESI JPM, BIOCHINA will lead a one-hour China-focused session exploring how AI, innovation capabilities, and evolving partnership models are shaping the next generation of Chinese biotech. The discussion will bring Chinese industry leaders into direct conversation with RESI’s global licensing and partnering community about emerging technologies, business opportunities, and international collaboration.

At BIOCHINA, LSN will lead a reciprocal one-hour session on how international partners evaluate emerging companies, assess the team behind the science, and build productive relationships with founders. Final session titles and speakers will be announced separately.

“Both communities are looking across borders for their next opportunity,” said Dennis Ford, Founder and CEO of Life Science Nation. “Chinese companies are developing assets that global pharma is evaluating for future pipelines. International companies are seeking scientific relationships, development capabilities, and partners in China. Our job is to bring the right people together and help those conversations turn into business.”

The collaboration gives both organizations a platform to build a two-way innovation bridge—helping Chinese companies reach international markets while opening connections into China for global companies and strategic partners. Joint promotion through newsletters, industry networks and digital channels will extend the programs’ reach and introduce participants to opportunities across both communities.

The relationship has a proven starting point: LSN and Enmore Healthcare co-organized the first RESI Shanghai on November 12, 2019. Their 2027 collaboration brings those networks together again to advance the next generation of international partnerships.

About Life Science Nation

Life Science Nation connects emerging companies across drugs, devices, diagnostics and digital health with global investors and licensing partners through its databases, education, investability assessments, campaign services and RESI conference series.

About BIOCHINA

Founded in 2016, BIOCHINA has grown into the Asia-Pacific’s leading biotech industry event, with over 33,000 registered attendees by 2026. Centered on evolving industry needs, BIOCHINA integrates Exhibition, Conference, Partnering, and Events to: Connect supply and demand across the value chain, Share the latest technological trends, Drive project collaborations and funding, Promote global biotech cooperation. Moving forward, BIOCHINA remains committed to connect Innovators & enable Bio-industry.

RESI: https://www.resiconference.com/
BIOCHINA: https://www.biocn.cn/

Meet Emerging Asian Life Science Innovators at Japan – Asia Life Science Showcase

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

We are excited to welcome back Kobe Biomedical Innovation Cluster (KBIC) as a Title Sponsor of RESI JPM 2027! Continuing our partnership, KBIC will once again bring together promising life science innovators from across Asia, connecting emerging technologies with the global investment and partnering community.  

As part of this collaboration, Japan – Asia Life Science Showcase will take place on January 11, 2027, from 1:00 – 3:00 PM at the San Francisco Marriott Marquis, during RESI JPM 2027.

This special two-hour showcase will feature eight innovative life science companies advancing technologies across oncology, regenerative medicine, cell therapy, infectious diseases, and medical technologies. From pioneering tooth regeneration therapies and next-generation cancer immunotherapies to engineered bacteriophages and brain-computer interfaces, these companies highlight the diversity and growing potential of Asia’s life science innovation ecosystem.

For investors, pharmaceutical companies, and business development professionals, this session offers an opportunity to discover emerging technologies and explore potential investment, licensing, and strategic partnership opportunities.

Meet the 8 Featured Companies

Toregem BioPharma Co., Ltd.  

Toregem BioPharma is developing a groundbreaking approach to tooth regeneration through its lead antibody candidate, TRG035, targeting USAG-1 to stimulate natural tooth development. Following Phase I clinical development, the company is advancing its program toward treating congenital tooth agenesis, with the potential to transform dental and regenerative medicine. 

Crafton Biotechnology Co., Ltd.  

Crafton Biotechnology is leveraging its proprietary PureCap® mRNA platform to develop next-generation therapeutics that enable sustained antibody production within the body. By potentially reducing treatment frequency and improving patient convenience, the company aims to address unmet medical needs in autoimmune and other chronic diseases. 

A-SEEDS Co., Ltd.  

A-SEEDS is advancing innovative CAR-T cell therapies targeting acute myeloid leukemia and solid tumors. Utilizing its proprietary non-viral piggyBac transposon platform, the company is developing durable, tumor-selective cell therapies designed to overcome key limitations of conventional CAR-T treatments. 

Arrowsmith Inc.  

Arrowsmith is harnessing synthetic biology to develop engineered bacteriophage therapies targeting antimicrobial-resistant infections. Its precision-based approach selectively eliminates harmful bacteria, including Pseudomonas aeruginosa, offering a potential alternative to conventional antibiotics in addressing the growing global antimicrobial resistance crisis. 

LIFESCAPES Inc. 

LIFESCAPES is developing non-invasive brain-computer interface (BCI) technology designed to restore hand movement in patients with severe paralysis resulting from stroke or spinal cord injury. By integrating brain signal monitoring, advanced software, and robotic assistance, its technology aims to improve rehabilitation outcomes and patients’ quality of life. 

Periotherapia Co., Ltd.  

Periotherapia is developing innovative antibody therapies targeting pathological periostin, a key component of the tumor microenvironment associated with treatment resistance. By disrupting protective barriers surrounding tumors, its approach aims to enhance drug penetration and improve the effectiveness of existing cancer therapies. 

CynosBio, Inc.  

CynosBio specializes in autologous cell therapies addressing unmet needs in ophthalmology and orthopedics. Its portfolio includes Sakracy, an approved regenerative therapy for severe ocular surface disorders in Japan, alongside a Phase III knee cartilage regeneration program, positioning the company for potential international clinical development and commercialization.

Mustbio Co., Ltd.  

Mustbio is advancing next-generation cancer immunotherapies through its proprietary multi-specific antibody platform. Its tri-specific fusion protein targets PD-1, VEGF, and IL-21 pathways to enhance anti-tumor immune responses and potentially overcome resistance to existing immunotherapies, particularly in patients with refractory or relapsed cancers.

Join Us at Japan – Asia Life Science Showcase during RESI JPM 2027! 

Date: Monday, January 11, 2027
Time: 1:00 – 3:00 PM (PST)
Location: San Francisco Marriott Marquis

RSVP for Japan – Asia Life Science Showcase

Whether you are an investor seeking promising early-stage opportunities, a pharmaceutical company exploring innovative technologies, or a business development professional looking to expand your network, Japan – Asia Life Science Showcase offers an opportunity to connect with emerging life science innovators from across Asia. 

Join us at RESI JPM 2027 to discover breakthrough technologies, meet innovative founders, and explore new opportunities for global collaboration! 

Register for RESI JPM 2027

Investor Perspectives: Meet the Investors at RESI JPM 2027

By Momo Yamamoto, Senior Investor Research Analyst, LSN

What are investors looking for in early-stage life science companies, and whom do they hope to meet during J.P. Morgan Healthcare Week? In this recurring feature, investors share their fund’s focus, what catches their attention, and what brings them to RESI JPM.
Watch three brief conversations below.

Markus Schreyer
The Ganesha Lab
Watch the interview:

Reza Sabahi
Tellaro Capital Partners
Watch the interview:

RESI JPM 2027 takes place in San Francisco on January 11–12, with virtual partnering days on January 13, 18, and 19. Learn more and register:

Register for RESI JPM 2027